Avantor (AVTR)
Health Care · Life Sciences Tools & Services · NYSE
A global provider of mission-critical products and services for laboratory research and production workflows across biopharma and advanced industries.
What Avantor does
Avantor provides mission-critical products and services to customers in the biopharma, healthcare, education, government, and advanced technology industries. Its portfolio includes a wide range of laboratory consumables, equipment, instruments, process chemicals, excipients, and fluid handling solutions, as well as specialized services for laboratory operations. The company operates through its VWR channel and specialized solution brands to support the complete laboratory and production workflow.
Themes: biopharma production, laboratory automation, semiconductor supply chain, scientific research support
Fundamentals
- Price$14.46 as of 2026-08-21 close
- Market cap$9.9B as of 2026-08-21
- 1-year return+15.1% 2025-08-21 close $12.56 → 2026-08-21 close $14.46
- P/En/a negative earnings
- Net margin-8.8% as of 2026-08-24
- Gross margin+31.8% as of 2026-08-24
- ROE-10.3% as of 2026-08-24
- Debt / equity0.66 as of 2026-08-24
- Revenue growth (YoY)-1.6% as of 2026-08-24
- Revenue CAGR (3y)-4.5% SEC XBRL
- Beta0.96 as of 2026-08-24
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
Dividend: does not currently pay a dividend.
How AVTR compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AVTR is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
43.4 #1215 of 1,704 scored · #196 of 240 in Health Care
Trend 81st: a strong uptrend, with buyers in control; volume and participation 54th: it gapped 16.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 35th: no Elliott-wave labelling currently fits its swings. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Avantor looks technically
Avantor (AVTR) is trading 40.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 13 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It just made a new 20-day high, its first since 2025-10-28, pushing above its recent trading range.
Trend
9
| Distance from the 200-day | it is trading 40.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +40.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.61 | $11.61 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.29 | $10.29 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 13.08. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 13 trading days ago — a "golden cross", a bullish long-term signal | 13 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 40.5% above | +40.5% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 45.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70) | 70.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($13.08 to $14.48) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.93 | $15.93 |
|---|---|---|
| From the 52-week high | it is 9.2% below its 52-week high (its highest price of the past year) | -9.2% |
| Above the 52-week low | it is 99.0% above its 52-week low (its lowest price of the past year) | +99.0% |
| Below the 52-week high | it is 9.2% below its highest point of the past year | 9.2% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2025-10-28, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2025-10-28, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $44.37 (set on 2021-09-23) | $44.37 |
| Given back of the 52-week move | over the past year its closes ranged ($7.41 to $15.60), and it has recovered almost all of its fall from last year’s high — 86% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.47 to $12.73. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 86.1% |
| From the all-time high | it is 67.4% below its all-time high | -67.4% |
| Nearest price level | it is trading 0.7% above a support level at $14.37 — a price it turned at four times since 2025-07-01, most recently on 2025-10-03. Since 2024-08-21 it has 11 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | its lowest closing price on record is $6.66 (set on 2020-03-18) | $6.66 |
| Above the all-time low | it is 117.3% above its all-time low | +117.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 39th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5096 between its high and its low — about 3.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5096 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.40 and $14.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.40 – $13.61 – $14.82 |
| Typical daily range (% of price) | its price moves about 3.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 8.2 daily ranges above its 200-day average price (40.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.56× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Open gap | it gapped 16.7% above the previous close 17 sessions ago and has not traded back through the level it left behind at 12.42 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +16.7% |
| Gap filled | a 3.2% gap down opened on 2026-07-31 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +8.48% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 29.2 percentage points (the stock gained 31.6% while the market gained 2.3%) | +29.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 80.6 percentage points (the stock gained 83.7% while the market gained 3.1%) | +80.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 49.1 percentage points (the stock gained 60.1% while the market gained 11.1%) | +49.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 5.4 percentage points (the stock gained 15.1% while the market gained 20.5%) | -5.3% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 39% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.8% of the share price. | +38.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 43% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.12 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +42.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $13.89 — a volume-weighted average of daily closes over 18 sessions, not a true tick-by-tick VWAP. | +4.1% |
Price levels it has turned at before
AVTR last closed at $14.46 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.37 | Support | 0.7% below the last close | turned there four times · 2025-07-01 to 2025-10-03 |
| $13.96 | Support | 3.5% below the last close | turned there twice · 2025-06-10 to 2025-08-25 |
| $13.68 | Support | 5.4% below the last close | turned there three times · 2025-04-09 to 2025-09-05 |
| $17.13 | Resistance | 18.4% above the last close | turned there twice · 2025-02-19 to 2025-03-19 |
| $20.76 | Resistance | 43.6% above the last close | turned there three times · 2024-12-05 to 2024-12-30 |
| $21.38 | Resistance | 47.9% above the last close | turned there three times · 2024-11-25 to 2025-01-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $13.08.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.51 and $16.83 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$14.56 range $12.00 – $19.00; median $14.20
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVTR
- Consensus EPS estimate$0.2082 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on sole or limited sources for essential materials and components","Ability to successfully integrate acquired businesses","Exposure to interest rate fluctuations on debt borrowings"]
What changed in the latest 10-Q
AI-assisted comparison of AVTR's 10-Q filed 2026-04-29 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-29): Added disclosure of segment change effective January 1, 2026, with company now operating through two segments: Bioscience & Medtech Products and VWR Distribution & Services
- Newer filing (2026-04-29): Added disclosure that segment change did not impact consolidated operating results but comparative period disclosures were revised
- Newer filing (2026-04-29): Added new factor 'Goodwill impairment risk — VWR Distribution' disclosing Q1 2026 triggering event from sustained share price decline requiring interim impairment assessment with limited margin of fair value over carrying value
- Newer filing (2026-04-29): Added specific financial metrics for Q1 2026: operating income of $99.5 million and Adjusted Operating Income of $190.6 million
- Newer filing (2026-04-29): Added language that tariff-related pressures have 'reduced' in trade policy factor, with ongoing uncertainty remaining
- Removed:
- Older filing (2025-10-29): Removed disclosure of Clinical Services divestiture completed October 17, 2024
- Older filing (2025-10-29): Removed factor 'We continue to invest in a differentiated innovation model' with details on customer engagement and product development in cell and gene therapy
- Older filing (2025-10-29): Removed factor 'We continue to advance our cost transformation initiative' disclosing initial $300 million gross cost savings target by end of 2026 and expanded $400 million target by end of 2027
- Older filing (2025-10-29): Removed original trade policy language stating tariffs and trade restrictions 'could' adversely affect business
- Reworded:
- Basis of presentation: Reference date changed from 'December 31, 2024' (older) to 'December 31, 2025' (newer)
- Overview period: Changed from 'three months ended September 30, 2025' (older) to 'three months ended March 31, 2026' (newer)
- Overview net sales: Changed from '$1,623.8 million' (older) to '$1,581.4 million' (newer)
- Overview net income: Changed from 'net loss of $711.8 million' (older) to 'net income of $43.3 million' (newer)
- Overview Adjusted EBITDA: Changed from '$267.9 million' (older) to '$219.4 million' (newer)
- Overview organic decline: Changed from '4.7% organic net sales decrease' (older) to '4.1% organic net sales decrease' (newer)
- Overview year-over-year comparison: Changed from '5.3% decline' (older) to 'remained flat' (newer)
- Adjusted Operating Income definition: Newer filing specifies it is 'operating income or loss adjusted' while older filed version states it is 'net income or loss adjusted'; newer lists different adjustment items without depreciation expense
- Notes:
- The two filings cover different interim periods (Q3 2025 vs Q1 2026) and have different comparison years, limiting direct comparability
- Segment disclosures were revised to conform to new structure but the underlying consolidated results were not impacted per the newer filing
- Adjusted Operating Income definition appears to differ between filings in baseline measure and adjustment items, though the comparison section was cut off in both texts
Risk Factors
- Added:
- Glossary entry 'Fluid Handling' added: Single use systems and integrated solutions used to support the production of biologic drugs and therapies (filed 2026-04-29)
- Glossary entry 'NuSil' added: Ultra-high purity medical and aerospace grade silicone formulations (filed 2026-04-29)
- Glossary entry 'Process Chemicals' added: Process ingredients and excipients used to support the production of biologic drugs and therapies (filed 2026-04-29)
- Glossary entry 'Research & Specialty Chemicals' added: Proprietary formulated solutions for semiconductor manufacturing and proprietary chemicals for healthcare, biopharma, diagnostic, and industrial applications (filed 2026-04-29)
- Glossary entry 'Services' added: Services and products designed to optimize and manage end-to-end laboratory operations for customers across industries such as biopharma, education, industrial, and technology sectors (filed 2026-04-29)
- Glossary entry 'VWR Channel' added: Mission-critical consumables, chemicals, and equipment and instrumentation used by scientists in their labs (filed 2026-04-29)
- Forward-looking statements reference changed from 'plans, including our cost transformation initiative' to 'plans' with no mention of cost transformation initiative (filed 2026-04-29)
- Cautionary factor changed from '(including impacts from the U.S government shutdown that started in October 2025)' to '(including impacts resulting from a U.S. government shutdown)' removing specific date reference (filed 2026-04-29)
- Cautionary factor changed from 'the impact of new laws, regulations, or other industry standards' to 'the impact of new laws, regulations, government policies or orders or other industry standards' adding government policies or orders (filed 2026-04-29)
- Cautionary factor changed from 'our ability to maintain our relationships with distributors' to 'our ability to maintain our relationships with suppliers' (filed 2026-04-29)
- Removed:
- Glossary entry 'Advanced Lab Services' removed (filed 2025-10-29)
- Glossary entry 'Applied Solutions' removed (filed 2025-10-29)
- Glossary entry 'ASC' (Accounting Standards Codification) removed (filed 2025-10-29)
- Glossary entry 'Bioprocessing' removed (filed 2025-10-29)
- Glossary entry 'Laboratory Specialty Products' removed (filed 2025-10-29)
- Glossary entry 'Silicones' removed (filed 2025-10-29)
- Glossary entry 'Total Science Solutions' removed (filed 2025-10-29)
- Annual Report reference changed from 'year ended December 31, 2024' to 'year ended December 31, 2025' (filed 2025-10-29)
- Reworded:
- Page numbers for Item 1A through Item 6 changed from 42-43 range (filed 2025-10-29) to 37-39 range (filed 2026-04-29)
- Glossary term capitalization: 'Long-term' changed to 'Long-term period' and 'short-term' changed to 'Short-term period' with capitalization standardized (filed 2026-04-29)
- Notes:
- Only the preliminary table of contents and cautionary factors sections are included in both excerpts; the detailed Risk Factors content (Item 1A) itself is not provided for comparison
- The glossary appears to have been reorganized to reflect different business segment naming conventions between the two filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days2 buys ($286700) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-05-08. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVTR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for AVTR from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding AVTR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 94,826,271
- Reported value $743,437,963
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AVTR had 53,171,919 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AVTR had 7.79% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.37 days to cover at the same settlement.
- Reported short interest (shares) 53,171,919
- Short interest (% of shares outstanding) 7.79%
- Prior settlement (shares) 55,976,133
- Reported change -5.01%
- Days to cover (reported) 3.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Merck KGaA (MRK.DE)
- Waters Corporation (WAT)
- Agilent Technologies (A)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVTR vs…
Frequently asked questions
What does Avantor (AVTR) do?
Avantor provides mission-critical products and services to customers in the biopharma, healthcare, education, government, and advanced technology industries. Its portfolio includes a wide range of laboratory consumables, equipment, instruments, process chemicals, excipients, and fluid handling solutions, as well as specialized services for laboratory operations.
What sector is Avantor (AVTR) in?
Avantor (AVTR) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NYSE.
Does AVTR pay a dividend?
No — Avantor (AVTR) does not currently pay a dividend (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Avantor's (AVTR) competitors?
Notable peers of Avantor (AVTR) include Thermo Fisher Scientific, Danaher, Merck KGaA, Waters Corporation and Agilent Technologies. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in AVTR?
Yes — we hold 5 matched STOCK Act disclosures for AVTR from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Avantor (AVTR) overbought or oversold right now?
Avantor (AVTR) is currently in overbought territory (its 14-day RSI is 71, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVTR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.